ArticleTherapeutic advances in medical oncology2024

Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28).

Yifan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.